| Acacia Pharma Ltd. – Product Pipeline Review – H2 2011 |
| Publication Date |
Nov 2011 |
| Publisher |
Global Markets Direct |
| Product Type |
Report |
| Pages |
35 |
| Single User License |
$
500.00 |
| Site User License |
$
1000.00 |
| Corporate User License |
$
1500.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
Acacia Pharma Ltd. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Acacia Pharma Ltd. - Product Pipeline Review - H2 2011” provides data on the Acacia Pharma Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Acacia Pharma Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Acacia Pharma Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Acacia Pharma Ltd. - Brief Acacia Pharma Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acacia Pharma Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Acacia Pharma Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Acacia Pharma Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Acacia Pharma Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Acacia Pharma Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Acacia Pharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Acacia Pharma Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Acacia Pharma Ltd. and identify potential opportunities in those areas.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Acacia Pharma Ltd. Snapshot 5
Acacia Pharma Ltd. Overview 5
Key Information 5
Key Facts 5
Acacia Pharma Ltd. – Research and Development Overview 6
Key Therapeutic Areas 6
Acacia Pharma Ltd. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Acacia Pharma Ltd. – Pipeline Products Glance 9
Acacia Pharma Ltd. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Acacia Pharma Ltd. – Drug Profiles 11
APD209 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
APD403 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
APD421 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
APD515 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Acacia Pharma Ltd. – Pipeline Analysis 15
Acacia Pharma Ltd. – Pipeline Products by Therapeutic Class 15
Acacia Pharma Ltd. - Pipeline Products By Target 16
Acacia Pharma Ltd. – Pipeline Products by Route of Administration 17
Acacia Pharma Ltd. – Pipeline Products by Molecule Type 18
Acacia Pharma Ltd. – Recent Pipeline Updates 19
Acacia Pharma Ltd. - Dormant Projects 20
Acacia Pharma Ltd. - Discontinued Pipeline Products 21
Discontinued Pipeline Product Profiles 21
APD405 21
Acacia Pharma Ltd. – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Mar 31, 2009: Acacia Pharma Initiates Phase IIa Study With APD209 In Cancer Cachexia Patients 23
Sep 22, 2008: Acacia Pharma Starts First Clinical Trial With APD 405 For Nausea & Vomiting 23
Feb 16, 2011: Acacia Pharma Initiates Phase IIa Clinical Trial With APD421 For Nausea And Vomiting 24
Dec 14, 2009: Acacia Pharma Completes Phase II Study With APD405 In Post-Operative Nausea & Vomiting (PONV) 24
Jun 08, 2009: Acacia Pharma Initiates Phase II Study With APD405 In Post-Operative Nausea & Vomiting (PONV) 25
Sep 07, 2010: Acacia Pharma To Progress Two Projects For Nausea & Vomiting And Xerostomia Into Clinical Development 26
Feb 07, 2011: Acacia Pharma Completes Phase I Clinical Trial With APD515 For Xerostomia 27
Sep 06, 2010: Acacia Pharma To Progress Two Projects For Nausea & Vomiting And Xerostomia Into Clinical Development 27
Jan 06, 2011: Acacia Pharma Starts Clinical Trial With APD515 In Xerostomia 28
Jan 06, 2009: Acacia Pharma Completes Clinical Trial With APD 405 For Nausea & Vomiting 28
Financial Deals Landscape 30
Acacia Pharma Ltd., Deals Summary 30
Acacia Pharma Ltd., Pharmaceuticals & Healthcare, Deal Details 31
Venture Financing 31
Acacia Pharma Secures $10 Million In Series A Financing Round 31
Acacia Pharma Secures Investment From Gilde Healthcare Partners 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35List of Tables
Acacia Pharma Ltd. – Pipeline by Therapy Area and Indication, H2 2011 7
Acacia Pharma Ltd. – Pipeline by Stage of Development, H2 2011 8
Acacia Pharma Ltd. - Phase II, H2 2011 9
Acacia Pharma Ltd. - Phase I, H2 2011 10
Acacia Pharma Ltd. - Pipeline By Therapeutic Class, H2 2011 15
Acacia Pharma Ltd. - Pipeline By Target, H2 2011 16
Acacia Pharma Ltd. – Pipeline By Route of Administration, H2 2011 17
Acacia Pharma Ltd. – Pipeline By Molecule Type, H2 2011 18
Acacia Pharma Ltd. – Recent Pipeline Updates, H2 2011 19
Acacia Pharma Ltd. - Dormant Developmental Projects, 2010 20
Acacia Pharma Ltd. - Discontinued Pipeline Products, 2010 21
Acacia Pharma Ltd., Deals Summary 30
Acacia Pharma Secures $10 Million In Series A Financing Round 31
Acacia Pharma Secures Investment From Gilde Healthcare Partners 33List of Figures
Acacia Pharma Ltd. – Pipeline by Therapy Area and Indication, H2 2011 7
Acacia Pharma Ltd. – Pipeline by Stage of Development, H2 2011 8
Acacia Pharma Ltd. – Pipeline By Therapeutic Class, H2 2011 15
Acacia Pharma Ltd. – Pipeline By Route of Administration, H2 2011 17
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
| By Netscribes (India) Pvt. Ltd. |
| |
|
May 2012 |
$0.00 |
| Medical Devices Market in Russia 2009-2013 |
| By Infiniti Research Ltd |
| Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
|
|
Mar 2010 |
$1500.00 |
|
|
Jan 2013 |
$250.00 |
|
|
Jan 2012 |
$250.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
| 2010 U.S. HMO Medical Centers Industry Report |
| By Barnes Reports |
| The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
|
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
